Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Alterations in Sleep EEG Biomarkers of Memory Consolidation in Middle-Aged and Older Adults.

bioRxiv : the preprint server for biology·2026
Same author

Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.

medRxiv : the preprint server for health sciences·2026
Same author

Longitudinal, Intra-Individual Stability of Untargeted Plasma and Cerebrospinal Fluid Metabolites.

Metabolites·2026
Same author

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Ramiro Eduardo Rea Reyes1, Rachael E Wilson2, Julie E Oomens3

  • 1Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Higher body mass is linked to lower plasma pTau217 levels, a key Alzheimer's disease (AD) biomarker. Adjusting for corpulence may improve early AD detection using blood tests.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurodegenerative diseases
  • Biomarker discovery
  • Alzheimer's disease diagnostics

Background:

  • Plasma pTau217 is a validated biomarker for amyloid pathology in Alzheimer's disease (AD).
  • Factors such as body mass (corpulence) may influence the accuracy of pTau217 measurements.
  • Understanding corpulence's impact is crucial for early AD detection studies.

Purpose of the Study:

  • To investigate the effect of corpulence on plasma pTau217 concentrations.
  • To assess the influence of corpulence on other AD-related blood biomarkers.
  • To determine the impact of corpulence on the classification accuracy of amyloid positivity using pTau217.

Main Methods:

  • Analysis of longitudinal plasma samples from 746 participants in AD research cohorts.
  • Measurement of plasma biomarkers including pTau217, GFAP, NfL, Aβ40, and Aβ42.
  • Modeling biomarker levels using mixed gamma regression, incorporating age, corpulence, APOEε4 carriage, and sex.

Main Results:

  • Increased corpulence was associated with a 4-5% reduction in plasma pTau217 levels in both amyloid accumulators and non-accumulators.
  • This reduction in pTau217 due to corpulence equates to approximately 3.25 years of delay in reaching the diagnostic threshold for individuals with obesity.
  • Similar reductions were observed for GFAP and NfL, but not for the Aβ42/Aβ40 ratio.

Conclusions:

  • Corpulence significantly influences plasma levels of key AD biomarkers, including pTau217, GFAP, and NfL.
  • Accounting for body mass in analyses may enhance the precision of plasma-based AD biomarker measurements.
  • Adjusting for corpulence could significantly improve the early detection of Alzheimer's disease using blood tests.